Meningococcal Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine), By End user (Hospitals, Clinic, Others) and Region Forecast 2021-2032

Meningococcal Vaccine Market size was valued at US$ 6.4 billion in 2025 and is expected to reach US$ 9.6 billion by 2032, growing at a significant CAGR of 6.0% from 2026-2032. Meningococcal disease is a fatal disease caused by Neisseria Meningitides, which causes potential infection in the meninges, the thin layers of connective tissues surrounding the spinal cord and brain. Common symptoms are bacteremia, pneumonia, and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes, and lethargy. The surge in the incidence of meningococcal disease is expected to play a vital role in growth of the global market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions.

According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has negatively impacted humanity, so various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of the disease, government initiatives, increased R&D investments by various players, and introduction of advanced vaccines are expected to boost the growth of the meningococcal vaccines market. However, lack of awareness, the high cost of vaccines, unfavourable regulatory conditions are restraining of global market.

Key Developments:

• In May 2025, the FDA expanded the indication of Sanofi’s quadrivalent meningococcal vaccine, MenQuadfi, to protect children aged 6 weeks to 23 months against invasive meningococcal disease caused by serogroups A, C, W, and Y. Originally approved in April 2020 for individuals aged 2 years and older, the vaccine’s broader use is supported by results from multiple phase 2 and 3 clinical trials.
• In February 2025, GSK plc announced FDA approval of Penmenvy, a meningococcal vaccine for individuals aged 10 to 25 years. The vaccine protects against five key Neisseria meningitidis serogroups A, B, C, W, and Y that are commonly responsible for invasive meningococcal disease (IMD).